41301-66-0

Basic information

• Product Name: ETHYL 1-(2-ETHOXY-2-OXOETHYL)-2-OXOCYCLOPENTANECARBOXYLATE
• Synonyms: ETHYL 1-(2-ETHOXY-2-OXOETHYL)-2-OXOCYCLOPENTANECARBOXYLATE;1-ETHOXYCARBONYLMETHYL-2-OXO-CYCLOPENTANECARBOXYLIC ACID ETHYL ESTER;2-Carbethoxy-2-(carbethoxymethyl)-1-cyclopentanone;ethyl 1-(2-ethoxy-2-oxoethyl)-2-oxocyclopentanecarboxylate(WXC09114)
• CAS NO: 41301-66-0
• Molecular Formula: C₁₂H₁₈O₅
• Molecular Weight: 242.27
• Mol File: 41301-66-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL 1-(2-ETHOXY-2-OXOETHYL)-2-OXOCYCLOPENTANECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 1-(2-ETHOXY-2-OXOETHYL)-2-OXOCYCLOPENTANECARBOXYLATE(41301-66-0)
• EPA Substance Registry System: ETHYL 1-(2-ETHOXY-2-OXOETHYL)-2-OXOCYCLOPENTANECARBOXYLATE(41301-66-0)

Safety Data

• Hazardous Substances Data: 41301-66-0(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Synthesis, p. 316, 1973 DOI: 10.1055/s-1973-22208

Upstream product

• 611-10-9 2-ethoxycarbonyl-1-cyclopentanone 
• 105-36-2 ethyl bromoacetate 
• 623-73-4 diazoacetic acid ethyl ester 
• 40702-70-3 ethyl 2-oxo-cyclopentanecarboxylate potassium salt 
• 105-39-5 chloroacetic acid ethyl ester 
• 141-28-6 diethyl adipate 

Downstream Products

• 91524-79-7 ethyl<3-(4-methylphenylsulfonyl-hydrazino)-2-ethoxycarbonylmethyl>-cyclopentane carboxylate 
• 104115-44-8 (2-oxocyclopent)acetic acid 
• 1206125-32-7 ethyl 7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-3-(2-ethoxy-2-oxoethyl)-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylate 
• 1206123-97-8 (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, L-arginine salt 
• 1206123-37-6 [(3R)-7-{[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy}-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid 
• 1206124-34-6 (R/S)-ethyl 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate 

Relevant articles and documents

C-8-quaternary prostaglandin analogs

A simple and convenient synthesis of the title compounds is presented.

A novel Fischer pseudo-benzylic decarboxylation approach to the 1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl system

A novel Fischer pseudo-benzylic decarboxylation approach to the 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl system was developed starting from geminally substituted cyclopentanone derivatives and appropriately substituted phenyl hydrazines. In addition, we demonstrate that substituents at the 3- and 7-positions can, for example, be useful synthetic handles for further functionalization.

PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF

The present invention relates to processes and intermediates useful in the preparation of of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

Baeyer-Villiger oxidations catalyzed by engineered microorganisms: Enantioselective synthesis of δ-valerolactones with functionalized chains

Cyclohexanone monooxygenase (CHMO) from Acinetobacter sp NCIMB 9871 expressed in baker's yeast and in E. coli and cyclopentanone monooxygenase (CPMO) from Comamonas (previously Pseudomonas) sp. NCIMB 9872 expressed in E. coli are new bioreagents for Baeye

Syntheses of the Terpenoid Precursors Cyclopent-2-enone and Cyclohex-2-enone Diesters

Two reaction pathways were elaborated for the practical and convenient syntheses of the title compounds.The first route applies a bromination-dehydrobromination sequence to introduce the double bond into 1-alkoxycarbonyl-2-oxocycloalkylacetic and propioni

CATALYST DEPENDENT MECHANISTIC PATHS IN THE REACTIONS OF ETHYL DIAZOACETATE WITH β-KETO ESTERS

The catalyzed decomposition of ethyl diazoacetate in the presence of β-keto esters produces regioisomeric enol ethers and the diester from formal carbenoid insertion into the α-C-H bond.The product distribution is very catalyst dependent.

TOTAL SYNTHESIS AND PROPERTIES OF PROSTAGLANDINS. VI. THE STEREOSPECIFICITY OF THE REDUCTION OF SOME γ-KETO ESTERS (MODELS OF PROSTAGLANDINS OF THE E SERIES) WITH SODIUM BOROHYDRIDE

The degree of stereospecificity in the reduction of cyclopentanone γ-keto esters with sodium borohydride was investigated with respect to the presence of substituents at the C2, C3, or C4 atoms of the cyclopentane ring.It was found that they have different effective directing effects on cis attack by the borohydride ion (cis in relation to the substituent at the C2 atom).It is suggested that the substituent which directs the BH4(1-) ion "to its own side" and gives rise to the degree of stereospecificity in the reduction is the alkoxycarbonyl group at the C2 atom of the cyclopentanone ring in the γ-keto esters.

Derivatives of 9-oxo-13-trans-prostenoic acid esters

This disclosure describes homologues, analogues, congeners, and derivatives of 9-oxo-13-trans-prostenoic acid and of 9-hydroxy-13-trans-prostenoic acid, having antimicrobial activity and prostaglandin-like hypotensive activity.